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Role of Sonic hedgehog signaling and the expression of
its components in human embryonic stem cells
Selena Meiyun Wu a, Andre B.H. Choo a,b,
Miranda G.S. Yap a , Ken Kwok-Keung Chan a,⁎a Stem Cell Group, Bioprocessing Technology Institute, A⁎STAR (Agency for Science, Technology and Research),
20 Biopolis Way, No. 06-01 Centros, Singapore 138668, Singapore
b Division of Bioengineering, National University of Singapore, SingaporeReceived 22 June 2009; received in revised form 7 September 2009; accepted 8 September 2009Abstract Human embryonic stem cells (hESC) are characterized by their ability to self-renew and differentiate into all cell
types of the body, making them a valuable resource for regenerative medicine. Yet, the molecular mechanisms by which hESC
retain their capacity for self-renewal and differentiation remain unclear. The Hedgehog signaling pathway plays a pivotal role in
organogenesis and differentiation during development, and is also involved in the proliferation and cell-fate specification of
neural stem cells and neural crest stem cells. As there has been no detailed study of the Sonic hedgehog (SHH) signaling pathway
in hESC, this study examines the expression and functional role of SHH during hESC self-renewal and differentiation. Here, we
show the gene and protein expression of key components of the SHH signaling pathway in hESC and differentiated embryoid
bodies. Despite the presence of functioning pathway components, SHH plays a minimal role in maintaining pluripotency and
regulating proliferation of undifferentiated hESC. However, during differentiation with retinoic acid, a GLI-responsive
luciferase assay and target genes PTCH1 and GLI1 expression reveal that the SHH signaling pathway is highly activated. Besides,
addition of exogenous SHH to hESC differentiated as embryoid bodies increases the expression of neuroectodermal markers
Nestin, SOX1, MAP2, MSI1, and MSX1, suggesting that SHH signaling is important during hESC differentiation toward the
neuroectodermal lineage. Our findings provide a new insight in understanding the SHH signaling in hESC and the further
development of hESC differentiation for regenerative medicine.
© 2009 Elsevier B.V. All rights reserved.Introduction
Human embryonic stem cells (hESC) are pluripotent cells
capable of self-renewal and differentiation into lineages
representative of all three primary germ layers (Thomson
et al., 1998). These unique properties impart hESC the
potential to be used in cell replacement therapy. It is
essential that the mechanisms governing self-renewal and
pluripotency be understood before they can be used in⁎ Corresponding author. Fax: +65 6478 9561.
E-mail address: ken_chan@bti.a-star.edu.sg (K.K.-K. Chan).
1873-5061/$ – see front matter © 2009 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2009.09.002regenerative medicine. The developmentally important
Fibroblast Growth Factor (FGF) and Activin/Nodal signaling
pathways have been identified as fundamental pathways
governing hESC self-renewal and pluripotency (Vallier et al.,
2005). However, another important signaling pathway in
early embryology is the Hedgehog (HH) pathway whose
function and mechanism in hESC is less well understood.
HH signaling is a highly conserved pathway that plays a
pivotal role in cell proliferation and differentiation during
development. It mediates myriad embryonic processes such
as cell fate specification in the central nervous system, and
limb patterning and development of the bone, cartilage,.
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and McMahon, 2001). HH proteins are potent morphogens
capable of acting through long distances. In mammals, there
are three HH family ligands: Sonic hedgehog (SHH), Indian
hedgehog (IHH), and Desert hedgehog (DHH) which are
synthesized as approximately 45-kDa precursors that under-
go proteolytic autoprocessing and cholesterol modification
to produce the active N-terminal fragments (Porter et al.,
1996). The HH pathway signals via two transmembrane
proteins, Smoothened (SMO) and its negative regulator,
Patched1 (PTCH1). Other components of the pathway
include the GLI family of transcriptional effectors GLI1,
GLI2, and GLI3, whereby GLI1 acts as a transcriptional
activator while GLI2 and GLI3 are able to act as both
activators and repressors (Sasaki et al., 1999; Pan and Wang,
2007; Wang et al., 2000). In the absence of the HH ligand,
PTCH1 inhibits SMO resulting in the cleavage of GLI to the N-
terminal repressor form lacking an activation domain. On HH
binding to PTCH1, the inhibitory effect on SMO is relieved,
GLI repressor formation is inhibited, and full-length tran-
scriptional activators are transported to the nucleus. This
results in the transcription of HH target genes which include
PTCH1 and GLI1 (reviewed in (Hooper and Scott, 2005; Ruiz i
Altaba et al., 2002)). HH activity is regulated by the inhi-
bitory Hedgehog-interacting protein (HIP) that binds directly
with SHH (Chuang and McMahon, 1999). Another negative
regulator of the pathway is Suppressor of Fused (SUFU) that
interacts directly with the GLI proteins and sequestering it in
the cytoplasm, thus reducing the ability of GLI to initiate
transcription (Kogerman et al., 1999; Dunaeva et al., 2003).
One of the most extensively studied functions of SHH is its
role in the dorsal ventral patterning of the neural tube during
the development of the central nervous system in verte-
brates. SHH derived from the notochord forms a concentra-
tion gradient of SHH along the dorsal ventral axis in the
overlying neural tube, resulting in the specification of
diverse and distinct neuronal cell fates (Briscoe et al.,
1999). Its importance in embryonic development is also
reflected in its in vitro counterpart, embryonic stem (ES)
cells. During mouse embryonic stem cell (mESC) differenti-
ation, the pathway antagonist forskolin inhibited the
formation of the ectoderm layer in embryoid bodies (EBs)
(Maye et al., 2000). SHH is also used as a patterning factor in
various ES cell differentiation protocols. When applied in
conjunction with other molecules like FGF8 or retinoic acid
(RA) at different stages of differentiation, SHH promotes the
differentiation to neuronal subtypes like ventral spinal
progenitors (Li et al., 2008), dopaminergic neurons (Yan
et al., 2005; Perrier et al., 2004; Roy et al., 2006), motor
neurons (Wichterle et al., 2002), and dorsal interneurons
(Murashov et al., 2005). Apart from its role in differentiation,
it has been suggested that SHH signaling could play a role in
hESC self-renewal. In genome-wide studies of transcriptional
networks in mESC and hESC, the key regulators of pluripo-
tency OCT4, SOX2, and NANOG were found to occupy sites
upstream of PTCH1 and GLI3 (Boyer et al., 2005; Loh et al.,
2006). Moreover, downregulation of OCT4 in hESC resulted in
reduced levels of PTCH1 and GLI3 (Babaie et al., 2007),
suggesting that they are downstream targets involved in
maintaining hESC pluripotency.
Therefore, this study aims to elucidate the function of
SHH signaling pathway in hESC and their differentiatedprogenies. Our results indicate that components of SHH
signaling are expressed in undifferentiated hESC and diffe-
rentiated EBs as shown by immuofluorescent staining and
RT-PCR. We found that SHH signaling is minimal in hESC in
the undifferentiated state but is upregulated during diffe-
rentiation. SHH does not play a role in maintaining the
undifferentiated hESC phenotype or regulating the prolife-
ration of hESC. However, results showed that SHH influences
the lineage determination of hESC during differentiation as
confirmed by the increased expression of neuroectodermal
markers. Thus, our results presented here extend the
understanding of extrinsic factors regulating hESC pluripo-
tency and self-renewal.
Results
Expression of SHH signaling pathway components
To determine whether SHH signaling is present in hESC,
components of the SHH signaling pathway were analyzed by
immunocytochemistry. PTCH1 and SMO receptors were
localized to the plasma membrane while GLI1 and GLI3
colocalized with the nuclear dye, DAPI (Figs. 1A–D). The
expression of pathway components was further confirmed by
RT-PCR where low expression of SHH and IHH was detected
whereas DHH was undetectable in undifferentiated hESC.
hESC also express the PTCH1 and SMO but not PTCH2
receptors and transcription factors GLI1 and GLI3, along
with the pluripotent marker OCT4 (Fig. 1E). This confirms
that hESC express SHH signaling components necessary for
signal transduction. During spontaneous differentiation,
gene expression of SHH, DHH, and IHH in embryoid bodies
was significantly higher compared to hESC over the entire
14-day differentiation period. Concomitantly, there was also
an upregulation of GLI3, Hedgehog interacting protein (HIP),
PTCH1, and PTCH2 and a downregulation of SMO and GLI1
(Fig. 1E). These results are consistent with previous data
(Sasaki et al., 1997), that reported similar mRNA expression
of pathway components in hESC and EBs. The presence of
these SHH pathway components suggests that SHH signaling
cascades may have functional importance in undifferentia-
ted hESC and EBs.
Activation of SHH signaling in undifferentiated hESC
and role of GLI mediators
The presence of the SHH pathway components in hESC led us
to investigate if SHH signaling is active in undifferentiated
hESC. This was achieved using the GLI-mediated transcrip-
tional activation assay with GLI-responsive luciferase report-
er plasmid (8XGli-BS) (Rho et al., 2006). Transfection of the
8XGli-BS luciferase reporter plasmid into hESC showed 7-fold
induction of luciferase activity, as compared to the
background luciferase levels of the 8XmutGli-BS luciferase
reporter plasmid, indicating that there is endogenous
activation of the SHH pathway in undifferentiated hESC
(Fig. 2A).
To identify the role of GLI mediators in undifferentiated
hESC, three GLI mediators, GLI1, GLI2, and GLI3 expression
vectors, were also cotransfected with the wildtype 8XGli-BS
or 8XmutGli-BS luciferase reporter plasmid into hESC.
Figure 1 hESC express SHH pathway components. (A–D) Representative images showing immunofluorescent staining of (A) PTCH1,
(B) SMO, (C) GLI1, (D) GLI3 in hESC. Middle panel shows corresponding DAPI nuclear staining in blue and right panel shows
corresponding merged images. Scale bars represent 100 μm. (E) RT-PCR analysis of SHH signaling components in undifferentiated hESC
and differentiating EBs over 14 days.
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3-fold increase in wildtype 8XGli-BS luciferase activity,
respectively, while expression of GLI3 in hESC inhibited
8XGli-BS luciferase activity (Fig. 2A). Coexpression of GLI3
and GLI1 in hESC showed that GLI3 suppressed luciferase
reporter activation by GLI1 in a dose-dependent manner
(Fig. 2B). Another component of the SHH pathway, SUFU, a
negative regulator of GLI mediators, was also found to
significantly downregulate luciferase activity when it was
coexpressed with GLI1 in hESC (Fig. 2C). These results are
consistent with those previously reported (Stone et al., 1999)
and confirm the role of the GLI mediators in SHH signal
transduction in hESC.
Effect of SHH on hESC pluripotency and
proliferation
Since the SHH pathway was shown to be active in hESC, we
examined whether addition of exogenous SHH affects hESCpluripotency. hESC were cultured in conditioned medium
(CM) for two passages with or without 1 μg/ml recombinant
SHH and pluripotent surface marker Tra-1-60 expression was
evaluated by flow cytometry analysis. Results showed that
cells cultured over two passages in CM + SHH maintained high
levels of Tra-1-60 expression which are comparable to cells
cultured in CM (Fig. 3A). Similarly, quantitative real-time
PCR analysis of pluripotent markers OCT4 and NANOG
showed that cells cultured in CM or CM + SHH had similar
gene expression levels (Fig. 3B). Therefore, hESC remained
undifferentiated in the presence of SHH, suggesting that SHH
does not induce differentiation.
We were then interested to know if SHH maintains
pluripotency when hESC are grown under spontaneous
differentiation conditions. Cells were cultured in CM without
FGF2 (CM – FGF2) to induce spontaneous differentiation, as
FGF2 in CM has been shown to be necessary in the
maintenance of pluripotency (Greber et al., 2007). After the
second passage, there was a drop in expression of Tra-1-60,
Figure 2 GLI mediators are functioning in undifferentiated
hESC. Luciferase activity of 8XxGli-BS luciferase reporter
plasmid. (A) hESC were transiently transfected with 8XGli-BS
or 8XmutGli-BS luciferase reporter plasmid together with the
indicated expression vectors encoding GLI1, GLI2, and GLI3. (B,
C) The 8XGli-BS luciferase reporter plasmid and GLI1 expression
vector were cotransfected with increasing concentrations of (B)
GLI3 and (C) SUFU expression vector as indicated. Luciferase
activities were calculated as a ratio of Firefly luciferase activity
over Renilla luciferase activity and expressed as fold induction
relative to vector control. Values shown are mean±SD of a
representative experiment carried out in triplicate and repeat-
ed at least three times.
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cultured in CM (Figs. 3A and B), indicating that cells were
undergoing spontaneous differentiation. When 1 μg/ml
recombinant SHH was added daily to CM – FGF2 cells over
two passages (CM – FGF2+SHH), there was a similar decrease
in Tra-1-60, OCT4, and NANOG expression levels when
compared to CM – FGF2 cells (Figs. 3A and B). These resultssuggest that SHH treatment does not maintain pluripotency
of hESC and does not speed up the differentiation of hESC.
In order to study if SHH affects the proliferation of hESC,
an EdU incorporation assay was used to investigate the cell
proliferation of hESC after SHH treatment. hESC were
treated with 1 μg/ml recombinant SHH for 24 h and cells
were labeled with EdU during the last 2 h. Cells were
costained with the pluripotent marker OCT4 and analyzed by
flow cytometry. Results showed that despite treatment with
1 μg/ml SHH, the percentages of pluripotent OCT4 and EdU-
positive proliferating cells were similar to those of the
control (without SHH) (Fig. 3C). The effect of SHH on
apoptosis was also evaluated using the annexin V apoptosis
assay and the apoptotic cell population (annexin V positive
and PI negative) was similar in cells treated with or without
SHH (Fig. 3D). To further confirm our observations, an
alternative method of introducing exogenous recombinant
SHH was achieved by transfection of a CMV expression vector
encoding the full-length SHH into hESC as it has been
previously reported that recombinant HH protein and over-
expression of Ihh had similar biological effects (Deckelbaum
et al., 2002). Despite the differential expression of regula-
tory proteins both for cell cycle progression and for inhibition
on overexpression of SHH, there was no change in the
percentage of EdU-positive proliferating cells in the SHH
overexpression compared to vector control (Supplemental
Figs. 1A and B). Taken together, these results suggest that
SHH does not stimulate the proliferation of undifferentiated
hESC.
Activation of SHH signaling in hESC during
differentiation
Having established the activation of the SHH pathway in
undifferentiated hESC, we next studied the pathway
activation during early differentiation by interrogating SHH
target gene expression. hESC were either maintained in an
undifferentiated state with C or induced to differentiate by
culturing in differentiation medium (DM) or DM supplemen-
ted with 5 μM retinoic acid (DM + RA) for 96 h. Gene
expression of OCT4, NANOG, and the SHH target genes
PTCH1 and GLI1 was then analyzed by real-time PCR. When
cells were differentiated with DM, there was a 50% reduction
in OCT4 and NANOG gene expression compared to undiffe-
rentiated hESC, and addition of RA (DM + RA) abolished OCT4
and NANOG expression, showing loss of pluripotency
(Fig. 4A). The drop in pluripotency marker expressions was
accompanied by 1.5-fold upregulation of PTCH1 expression
in DM-treated cells and a 4-fold upregulation in DM + RA-
treated cells. GLI1 gene expression also increased by 2.5-
fold in DM + RA-treated cells, implying that the SHH pathway
is activated during differentiation.
In a different approach to the study of pathway
activation, the 8XGli-BS luciferase reporter plasmid was
transfected into hESC and treated under similar culture
conditions as above. No increase in luciferase activity was
observed for hESC cultured in DM. However, a significant
induction of luciferase activity (2-fold) was observed in
differentiating hESC treated with RA (DM + RA) (Fig. 4B). This
induction in luciferase activity was inhibited by cyclopamine,
a specific antagonist of the pathway that inhibits at the level
of the SMO receptor (Taipale et al., 2000). Addition of 10 μM
Figure 3 Exogenous SHH does not affect pluripotency and proliferation in undifferentiated hESC. (A) FACS analysis of Tra-1-60-
positive cells and (B) quantitative real-time PCR analysis of pluripotent markers OCT4 and NANOG expression in hESC maintained in
conditioned media (CM), CM supplemented with 1 μg/ml SHH (CM + SHH), CM without FGF2 (CM – FGF2), or CM without FGF2
supplemented with 1 μg/ml SHH (CM – FGF2 + SHH) over two passages. Gene expression was normalized to that of GAPDH and
expressed as percentages relative to undifferentiated hESC maintained in CM. The values shown are mean±SD of a representative
experiment performed in triplicate and repeated three times. ⁎Pb0.05; ns, nonsignificant. (C) FACS analysis of EdU incorporation
assay in undifferentiated hESC. Cells were synchronized with nocodazole for 16 h and then treated with or without 1 μg/ml SHH for
24 h. Representative dot plots showing EdU incorporation in hESC costained for OCT4. (D) FACS analysis of annexin V apoptosis assay in
undifferentiated hESC whereby cells were treated with or without 1 μg/ml SHH for 24 h prior to assay. Representative dot plots
showing apoptotic cells (annexin V positive and PI negative).
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a lower basal level as compared to the vehicle control in CM
and DM. There was also approximately 75% reduction in
luciferase activity in DM + RA cells as compared to vehicle
control under the same conditions (Fig. 4B). This indicates
that endogenous SHH ligands activated the SHH pathway
during differentiation as it is SMO dependent. Similarly, the
luciferase activity induction was also inhibited by forskolin,
an inhibitor of the pathway which activates protein kinase A
(PKA) which in turn phosphylates the GLI mediator proteinsto the repressor form (Wang et al., 2000; Sheng et al., 2006).
Here, the luciferase activity in all culture conditions was
significantly reduced by more than 50% with the addition of
50 μM forskolin as compared to vehicle control (Fig. 4B).
Together with the target gene expression studies, the results
provide evidence that endogenous SHH signaling in hESC is
present and can be further highly activated by the
endogenous SHH during RA-mediated differentiation.
As exogenous SHH is commonly added as a patterning
factor in hESC neuronal differentiation protocols, we wanted
43Role of SHH signaling in hESCto confirm that exogenous SHH activates the pathway during
differentiation. Hence, SHH was overexpressed along with
the 8XGli-BS luciferase reporter plasmid. Subsequently,
there was a 2-fold increase in luciferase activity in hESC
cultured in CM and in DM on overexpression of SHH compared
to the vector control (Fig. 4C). On top of that, over-
expression of SHH elicited a greater increase in luciferase
activity of around 3-fold in hESC cultured in DM + RA
compared to the vector control (Fig. 4C). This result
indicates that there is greater pathway activation by
exogenous SHH during hESC differentiation with RA. Speci-
ficity of SHH-induced luciferase activity was demonstrated
by the addition of 10 μM cyclopamine which resulted in a 50%
reduction in luciferase activity in cells cultured in CM, DM, or
DM + RA when compared to vehicle control. Overexpression
of GLI1 in this assay served as a positive control for pathway
activation (Fig. 4C). Exogenous SHH was also introduced in
the form of recombinant SHH to confirm the pathway
activation effect of overexpressing SHH ligand and similarFigure 4 Activation of SHH signaling by endogenous and
exogenous SHH. (A) Quantitative real-time PCR analysis of target
gene PTCH1 and pluripotent markers OCT4 and NANOG
expression in hESC maintained in conditioned media (CM), or
induced to differentiate with differentiation media (DM) or DM
supplemented 5 μM RA (DM + 5 μM RA) for 48 h. Gene expression
was normalized to that of GAPDH and expressed as percentages
relative to hESC in CM. The values shown are mean±SD of a
representative experiment performed in triplicate and repeated
twice. (B, C) Luciferase activity of the 8XGli-BS luciferase
reporter plasmid. hESC were transfected with the 8XGli-BS
luciferase reporter plasmid and cultured under similar condi-
tions as above for 48 h and then assayed for luciferase activity.
(B) Cells were treated with the vehicle control (DMSO/ethanol)
or pathway inhibitors 10 μM cyclopamine and 50 μM forskolin. (C)
SHH expression vector was cotransfected with the 8XGli-BS
luciferase reporter plasmid in the absence (vehicle-DMSO) or
presence of 10 μM cyclopamine. GLI1 was overexpressed as a
positive control. Luciferase activities were calculated as a ratio
of Firefly luciferase activity over Renilla luciferase activity and
expressed as fold induction relative to vehicle or vector control.
Values shown are mean±SD of a representative experiment
carried out in triplicate and repeated at least three times.
⁎ Pb0.05.results were obtained (Supplemental Fig. 2). Therefore, the
results indicate that both endogenous and exogenous SHH
can activate the pathway in hESC and higher activation
occurs during RA differentiation.
SHH signaling influences lineage determination
during spontaneous differentiation
Expression of key components of the SHH pathway in EBs and
its activation during differentiation suggest that SHH may
play a functional role during spontaneous differentiation. To
examine the effect of SHH signaling in lineage determination
during hESC differentiation, exogenous SHH secreted in the
conditioned medium (SHH-CM) of an inducible SHH over-
expressing cell line (293-EcR Shh) (Cooper et al., 1998) with
DM was used to culture differentiated hESC grown as EBs for
14 days. The levels of secreted SHH in SHH-CM were
confirmed using ELISA (data not shown). Conditioned media
from the normal HEK293 cells (Control-CM) was used as
control. Production of active N-terminal SHH from 293-EcR
Shh cells was used as a more convenient and economical
source of SHH than commercial recombinant SHH. Also its
usefulness in differentiation studies has been demonstrated
whereby the SHH producing cells were cocultured with mESC
to promote motor neuron differentiation (Soundararajan
et al., 2007).
After 14 days in culture with SHH, expressions of the
pluripotent marker OCT4, SHH target genes GLI1 and PTCH1,
and differentiation markers were analyzed using quantita-
tive real-time PCR. Long-term treatment of SHH-CM enabled
sustained activation of the SHH pathway as shown by the
upregulation of GLI1 and PTCH1 expression (Fig. 5A). OCT4
expression was downregulated under all conditions as
compared to undifferentiated hESC, indicating that the
media used did not inhibit the ability of cells to differentiate
(Fig. 5A). An increased expression of neuroectodermal
Figure 5 Neuroectoderm marker expressions are upregulated in EBs after 14 days of exposure to SHH. (A–C) EBs were grown in SHH-
CM or Control-CM suspension culture for 14 days and mRNA expression was analyzed by quantitative real-time RT-PCR to determine the
expression of (A) SHH target genes, (B) neuroectoderm, and (C) mesoderm and endoderm markers. Gene expression was normalized to
that of GAPDH and expressed as percentages relative to undifferentiated hESC. Values shown are mean±SD of a representative
experiment carried out in triplicate and repeated at least three times. ⁎ Pb0.05 (significant difference compared to Control-CM-
treated EBs). (D) Immunofluorescent staining of neural stem cell marker Nestin in SHH-CM and Control-CM-treated EBs. Middle panel
shows corresponding DAPI nuclear staining in blue and right panel shows corresponding merged images. Scale bars represent 50 μm.
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observed in SHH-CM-treated EBs compared to the control
group (Fig. 5B). The expressions of endodermal markers AFP
and GATA4 were not significantly altered, although a 30%
decrease in GATA6 mRNA was observed. IGF2, a mesoderm
marker, was downregulated, whereas there was no effect on
the COL2A expression level (Fig. 5C).
Following the 14-day differentiation in suspension, the
EBs were replated onto gelatin-coated dishes to furtherdifferentiate for an additional 7 days in SHH-CM or Control-
CM. Immunofluorescent staining results showed that in SHH-
CM-treated differentiated cells, the neural stem cell marker,
Nestin, is more highly expressed compared with Control-
CM-treated cells (Fig. 5D). Quantitative analysis also
confirmed that there was about 15 % increase in Nestin-
positive cells when treated with SHH (Supplemental Fig. 3).
Therefore, our results indicate that long-term exposure of
EBs to exogenous SHH promotes differentiation toward the
45Role of SHH signaling in hESCneuroectoderm lineage and increases Nestin-positive neural
derivatives, but with no significant influences on mesoder-
mal or endodermal lineages.
Discussion
In this study, we investigated the expression of SHH and its
pathway components in undifferentiated hESC and hESC
during EBs differentiation. We found that hESC express the
key components of the SHH signaling pathway, including the
receptors PTCH1, SMO, and transcription factors GLI1 and
GLI3 (Fig. 1). It was recently shown that the H1 and H9 hESC
lines possess primary cilia containing the SMO and PTCH1
receptors and the authors also found that low levels of SHH
are located at the base of the cilia (Kiprilov et al., 2008).
Primary cilia have been shown to be required for SHH
signaling to occur (Han et al., 2008) and preliminary data
indicate that primary cilia are present in our HES-3 hESC line
(unpublished data). It suggests that primary cilia and SHH
signaling are important in hESC and work is underway to
investigate the presence of SMO and PTCH1 receptors or
other important signaling receptors on the primary cilia of
undifferentiated and differentiated hESC.
Using a GLI-mediated transcriptional activation assay, we
detected that the SHH signaling pathway was active in
undifferentiated hESC (Fig. 2A). Results also established that
GLI1 and GLI2 were able to activate the pathway (Fig. 2A),
while GLI3 repressed GLI1-mediated activation (Fig. 2B), as
reported elsewhere (Sasaki et al., 1999; Taipale et al.,
2000). Another pathway component, SUFU that controls the
processing and activity of the GLI proteins (Lum et al., 2003);
(Ruel et al., 2003) was also shown expectedly to act as a
negative regulator of GLI1 in hESC (Fig. 2C). The results show
that the SHH pathway is present in hESC and the signaling
cascade downstream of SMO is functioning, supporting the
previous findings that PTCH1 and SMO receptors on the cilia
were responsive to SHH stimulation (Kiprilov et al., 2008).
Having established the presence of the SHH pathway in
hESC, we examined its function in hESC. Our results showed
that exogenous SHH did not induce differentiation of hESC
cultured in CM as there was no difference in levels of
pluripotent markers Tra-1-60, OCT4, and NANOG expression
in a 2-week culture with 1 μg/ml recombinant SHH. Removal
of FGF2 from CM resulted in spontaneous differentiation with
the loss of pluripotent markers and addition of recombinant
SHH did not increase the loss of pluripotent marker
expression nor did it increase the expression of pluripotent
markers (Figs. 3A and B). These observations are in line with
data reported by Heo et al. (Heo et al., 2007), whereby mESC
maintained their undifferentiated status with long-term
treatment of 0.5 μg/ml SHH over 5 passages. SHH was also
shown to stimulate undifferentiated mESC proliferation via
the canonical Gli pathway and noncanonical Ca2+/PKC and
EGF receptor activation. The authors observed an increase in
cell proliferation and cell cycle component expression on
stimulation with 50 ng/ml SHH (Heo et al., 2007). However,
in our study, we found that neither the addition of
recombinant SHH nor overexpression of SHH result in any
significant differences in cell proliferation or cell death
despite changes in the level of cyclin D1, a known SHH target
(Wechsler-Reya and Scott, 1999) (Figs. 3C and D; Supple-
mental Fig. 1A). This discrepancy could be due to theinherent difference in self-renewal properties between
mESC and hESC or that the stimulatory effect of SHH is
tissue specific as SHH has been shown, depending on the cell
type, to be a mitogen as well as a negative regulator of the
cell cycle (Neumann, 2005); (Roy and Ingham, 2002).
Therefore, although the SHH pathway is functional and
present in undifferentiated hESC, it does not appear to play a
role in self-renewal or pluripotency. Rather, we suggest that
the pathway is minimally activated in hESC and is poised for
activation on differentiation.
This hypothesis is supported by real-time PCR data that
show when cells were differentiated in DM with RA, there
was significant upregulation of the SHH target genes PTCH1
and GLI1 (Fig. 4A), indicating pathway activation. The GLI-
mediated transcriptional activation assay corroborated with
the target gene expression data, showing that the SHH path-
way was activated in cells in DM with RA, and that the
activation was SMO/GLI dependent (Fig. 4B). The SHH
pathway does not appear to be activated in DM-treated
cells because they were partially differentiated as demon-
strated by the presence of small amount of OCT4 and NANOG
transcripts (Fig. 4A). And on treatment with RA, a known
potent inducer of differentiation, there was rapid differen-
tiation as OCT4 and NANOG expression was downregulated,
and this was accompanied by high activation of the SHH
pathway (Fig. 4A). RA treatment has been shown to induce
the differentiating cells to express the SHH ligand (unpub-
lished data) (Okada et al., 2004), thereby highly activating
the SHH pathway. The GLI-mediated transcriptional activa-
tion assay also showed that there was the greatest pathway
activation by exogenous overexpressing SHH or recombinant
SHH when hESC were differentiated with RA (Fig. 4C;
Supplemental Fig. 2). This implies that in the undifferenti-
ated state, activation of the pathway by exogenous SHH is
minimal but when the cells begin to differentiate, they
become more responsive to SHH stimulation. RA is commonly
used in several ES cell differentiation protocols as a
caudalizing factor to generate differentiated cells of the
neural linage (Li et al., 2008; Wichterle et al., 2002;
Schuldiner et al., 2001; Bibel et al., 2004) and its function
could be partly attributed to its activation of the SHH
signaling pathway (Okada et al., 2004). Coupled with the
expression of SHH pathway components in EBs (Fig. 1E), SHH
could play a more important role during differentiation and
led us to study the effect of SHH signaling on the lineage
determination during early EBs differentiation.
During hESC differentiation as EBs, the aggregates consist
of various types of cells representing the three embryonic
germ layers, ectoderm, mesoderm and endoderm (Xu et al.,
2001), whose lineage commitment is governed by growth
factors (Schuldiner et al., 2000). Since SHH is a known
developmental patterning cue that regionalizes neural
progenitor cells, we investigated the effect of SHH on hESC
EBs differentiation by using SHH-CM. Here, we demonstrated
that CM containing SHH was able to influence hESC lineage
commitment to the neuroectoderm lineage as shown by the
increase in gene expression of neuroectoderm markers SOX1,
MSI1, MSX1, and MAP2. Differentiated hESC treated with
SHH also showed increase expression of Nestin, a neural stem
cell marker (Fig. 5; Supplemental Fig. 3). Our findings are
consistent with the report showing the requirement of HH
signaling in establishing the neuroectoderm in mESC EBs
46 S.M. Wu et al.whereby EBs derived from Smo or Ihh mESC mutant lines
were not be able to generate neuroectoderm and their
neural derivatives (Maye et al., 2004). The increase in
Nestin-positive differentiated cells from the SHH-treated
population could be due to SHH supporting the proliferation
of cells expressing Nestin. A recent study also showed that
SHH promoted the survival of Sox1-positive mESC-derived
neuroprogenitors (Cai et al., 2008). Similarly, current gain-
of-function studies have also found that SHH increases the
expression of Sox1 and Nestin in hESC-derived neuroprogeni-
tors using a defined neural differentiation protocol (unpu-
blished data).
In conclusion, this is the first study to show that the SHH
pathway is minimally active in undifferentiated hESC and
activation of SHH signaling does not maintain hESC pluripo-
tency and proliferation. Instead, SHH signaling is highly
activated during differentiation and influences the determi-
nation of early differentiated hESC toward the neuroecto-
dermal lineage. Our study significantly increases the
knowledge of SHH signaling in hESC and expands the
understanding of extrinsic factors regulating hESC pluripo-
tency. This understanding can be applied to control the
developmental fate of hESC during differentiation to achieve
a more efficient and homogenous population of the required
cell type for future regenerative medicine.
Materials and methods
Cell culture and reagents
Human embryonic stem cell lines HES-2 and HES-3 from ES
Cell International were cultured in medium conditioned by
mitomycin-C-inactivated immortalized mouse embryonic
fibroblast feeder (ΔE-MEF) supplemented with 10 ng/ml of
fibroblast growth factor-2 (FGF2) (Invitrogen) on Matrigel
(BD Bioscience)-coated plates as described (Chan et al.,
2008). ΔE-MEF conditioned medium contained Knockout-
DMEM (KO-DMEM) supplemented with 15% Knockout serum
replacer (KO-SR), 1% nonessential amino acids, 4 ng/ml
FGF2, 1 mM L-glutamine, and 1% penicillin-streptomycin (all
from Invitrogen) and 0.1 mM β-mercaptoethanol (Sigma).
Medium was changed daily. Cells were kept in a 5% CO2
incubator at 37 °C and passaged by mechanical dissociation
of colonies following collagenase IV treatment every 7 days.
HEK293 cells (CRL-1573) and 293-EcR Shh cells (CRL-2782)
were obtained from the American Type Culture Collection
(ATCC) and cultured at 37 °C/ 5% CO2 in complete medium
containing DMEM (high glucose) and 10% fetal bovine serum
(FBS) according to the manufacturer's protocol. Reagents
used for treatment of cells were nocodazole (Sigma),
cyclopamine (10 μM, Calbiochem), recombinant SHH N-
terminal protein (0.5–1 μg/ml, R&D Systems), forskolin
(50 μM, Sigma), and retinoic acid (5 μM, Sigma).
Embryoid body formation and differentiation
hESC were dissociated into small clumps by collagenase IV
and cultured in suspension as embryoid bodies in differen-
tiation medium (KO-DMEM supplemented with 20% fetal
bovine serum, 1% nonessential amino acids, 1 mM L-
glutamine, and 1% penicillin-streptomycin [all from Invitro-gen] and 0.1 mM β-mercaptoethanol [Sigma]) on ultralow
attachment plates (Corning). The culture was maintained in
suspension for 14 days. The EBs were then plated for 1 week
on gelatin-coated dishes for further differentiation.
Immunocytochemistry
hESC were fixed with 4% paraformaldehyde for 30 min and
permeabilized with 0.1% Triton X-100 in PBS for 30 min and
washed in PBS containing 1% BSA (PBS/BSA). Cells were
incubated overnight at 4 °C with primary antibodies: rabbit
anti-GLI1 and anti-PTCH1 (Abcam), rabbit anti-GLI3, anti-
SMO (Santa Cruz), and mouse anti-Nestin (Neuromics) at
1:100 dilutions. Cells were then incubated with secondary
antibody Alexa Fluor 488 (Invitrogen) for 2 h at room
temperature. Mounting medium containing DAPI (Vector
Lab) was used for nuclei counterstaining. Images were
acquired using a Zeiss Axiovert 200 M inverted fluorescent
microscope (Carl Zeiss). After immunostaining and images
capturing, the clusters were randomly picked up and the
population of Nestin-positive cells among total differentiat-
ed cells (DAPI-positive labeled nuclei) was counted and
scored within random at 400× magnification. Three to five
clusters in each group were counted and data were
expressed as mean±SEM.
RNA extraction, RT-PCR, and real-time PCR analysis
RNA was extracted with the RNeasy kit (Qiagen) and treated
with DNase according to the manufacturer's protocol. One
microgram of RNA was reverse-transcribed using Superscript
III Reverse Transcriptase (Invitrogen) and amplification of
genes was performed using Platinum Taq (Invitrogen) with a
program of 94 °C for 5 min, 30 cycles of 94 °C for 30 s, 54–
64 °C for 1 min, and 72 °C for 1 min and an extension step at
72 °C for 10 min. For real-time PCR analysis, all samples were
run in triplicates at a reaction volume of 25 μl containing
Power SYBR Green PCR Master Mix (Applied Biosystems), and
200 nM primers. The reaction was run on the ABI Prism7000
Sequence Detection System (Applied Biosystems) using the
following amplification parameters: 2 min at 50 °C, 10 min
at 95 °C, and 40 cycles of 15 s at 95 °C and 1 min at 60 °C.
Data were analyzed using the ΔΔCT method to obtain
expression levels relative to endogenous GAPDH control in
each sample as previously described (Chan et al., 2008). The
primers used for these analyses are listed in Supplemental
Tables 1 and 2.
Flow cytometry analysis
For detection of pluripotent markers OCT-4 and Tra-1-60,
cells were dissociated with trypsin and harvested as single
cells before fixation and permeabilization using Fix and Perm
Cell Permeabilization reagents (Invitrogen). Cells were
incubated with mouse monoclonal antibodies against OCT-4
(Santa Cruz) and Tra-1-60 (Chemicon), washed with PBS/
BSA, and then incubated with FITC-conjugated goat anti-
mouse secondary antibody (DAKO). Cells were washed and
resuspended in PBS/BSA for flow cytometry analysis. As a
negative control, cells were stained with the appropriate
isotype control. Cells were acquired using a FACS Calibur
47Role of SHH signaling in hESC(Becton Dickinson) and results were analyzed with the
CellQuest Software (Becton Dickinson).
Cell proliferation assay
To detect DNA synthesis in proliferating cells, incorporation
of a thymidine analog 5-ethynyl-2′-deoxyuridine (EdU) was
used (Invitrogen). hESC were transfected with the CMV
expression vector containing SHH (Open Biosystems) using
Lipofectamine 2000 (Invitrogen) and harvested 24, 48, and
96 h posttransfection, where EdU was added in 2 h prior to
harvest for assay. In a different approach, hESC were treated
with 10 mM nocodazole for 16 h for cell cycle synchroniza-
tion. Cells were then treated with 1 μg/ml recombinant SHH
for 24 h. EdU incorporation in cells was detected according to
the manufacturer's instructions by using a FACS Calibur
(Becton Dickinson) and results were analyzed with the
CellQuest Software (Becton Dickinson).
Apoptosis assay
hESC were treated with 1 μg/ml recombinant SHH for 24 h
and apoptosis assay was carried out using the annexin V-FITC
apoptosis detection kit (Bender MedSystems) according to
the manufacturer's instructions. Cells were counterstained
with propidium iodide (PI) to identify apoptotic cells.
Samples were analyzed on the FACS Calibur and results
were analyzed with the CellQuest Software (Becton
Dickinson).
Western blot analysis
hESC lysate prepared using 1% Igepal lysis buffer were
resolved on 4–12% NuPAGE gels (Invitrogen) and transferred
onto polyvinylidene fluoride (PVDF) membranes (BioRad).
Membranes were blocked in PBS with 5% low-fat milk and
probed overnight with primary antibodies; mouse anti-cyclin
A, anti-cyclin D1, anti-pRb, anti-p21, rabbit anti-p15 and
anti-SHH (Cell Signaling Technologies), mouse anti-OCT4,
and anti-actin (Santa Cruz). Anti-actin was used as a loading
control. This was followed by incubation with anti-rabbit or
anti-mouse horseradish peroxidase-conjugated secondary
antibodies (Amersham Biosciences) and signals were visual-
ized using the Immobilon Western Chemiluminescent HRP
Substrate (Millipore).
Transfection and luciferase reporter assay
CMV expression vectors containing mouse Gli1, mouse Gli2,
and human GLI3 were kind gifts from Chi-Chung Hui (Hospital
for Sick Children, Toronto, Canada). The 8XGli-BS luciferase
reporter plasmid containing 8 copies of Gli-binding sites and
8XmutGli-BS luciferase reporter plasmid containing 8 copies
of the mutated binding site were obtained as a gift from
Hiroshi Sasaki (Centre for Developmental Biology, Riken,
Japan) (Rho et al., 2006). The entire open-reading frame of
full-length human cDNA encoding Suppressor of Fused
(SUFU) (Open Biosystems) was subcloned into expression
vector pcDNA3.1(+) (Invitrogen) and sequence-verified. hESC
were plated in 24-well plates 4 days before transfection and
transfections were performed using Lipofectamine 2000(Invitrogen). The 8XGli-BS or 8XmutGli-BS luciferase reporter
plasmid was cotransfected with 20 ng TK-Renilla (pRL-TK)
(Promega) internal control plasmid and DNA expression
vectors as indicated. Wherever required, the total amount
of plasmid DNA transfected was adjusted to 1 μg by adding
the control plasmid pCDNA3.1(+) (Invitrogen). To induce
differentiation, hESC growth medium was changed 16 h after
transfection to DM or DM supplemented with 5 μM retinoic
acid (Sigma). Cells were harvested after 48 h and assayed for
luciferase activity using the Dual-Luciferase system (Pro-
mega) according to manufacturer's protocol. Luciferase
activities were measured for luminescence by the Infinite
M200 microplate reader (TECAN). Luciferase activities were
calculated as a ratio of Firefly luciferase activity over Re-
nillaluciferase activity and expressed relative to an empty
vector control. All transfection experiments were performed
at least with three biological replicates using different
batches of cells and preparations of plasmid DNAs and similar
results were obtained.
SHH-conditioned media production
To produce conditioned medium with SHH, 4×106 of 293-EcR
Shh cells and HEK293 cells as control were plated on T-175
flasks (Nalgene). Once the cells reached 50% confluence,
growth media were changed to DM and Ponasterone A
(Invitrogen) was added to293-EcR Shh cells to induce
expression of SHH. Culture medium was collected after
24 h and filtered through a 0.22-μm filter unit (Nalgene) and
used as growth media for hESC-derived EBs. Bulk quantities
of CM were produced and pooled to ensure consistency.
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